This text is a result of machine translation.
Cro plate fell, and Wuxi apptec fell nearly 10%
Singaporean Prime Minister Lee Hsien Loong meets with weifenghe
BiliBili CEO Chen Rui: station B will officially resume work on June 13
Tianci materials: it is planned to buy back the company's shares of RMB 250million to RMB 500million
The revenue of BiliBili in the first quarter was RMB 5.054 billion, which is expected to be RMB 5.042 billion.
CRO ClinChoice Raises USD 150 Mn in Series E Round
2015 is the inflection point for the development of China's innovative drug industry and CRO (clinical research organization). On July 22nd, 2015, after CDE (Center For Drug Evaluation) released the announcement on self-examination and verification of drug clinical trial data, the supervision of Chinese clinical trials moved towards standardization. The investment and financing of innovative drugs in China continued to increase, laying the foundation for the growth of CRO.
Jul 05, 2022 08:17 PM
The Influence of Leadership Change in Latin American Countries on Chinese Enterprises(One)
Sep 04, 2024 09:50 PM
Chinese Companies Going Overseas: Blindly Copying Foreign Companies is “Seeking Death”
Sep 04, 2024 08:37 PM